Growth Hormone-Releasing Hormone
The Non-Thyroidal Illness Syndrome
Madagascar. In Unknown Journal, Mar 2015
The best form of treatment (TRH,TSH,or T3+T4) and possible accompanying treatments (GHRH, Cortisol, nutrition, insulin) lack consensus.
Aging and age-related diseases--from endocrine therapy to target therapy.
Hangzhou, China. In Mol Cell Endocrinol, 2014
In this regard, the GHRH-GH-IGF-1/Insulin, TOR-S6K1,NAD(+)-Sirtuin, P53, Klotho and APOE pathways have been linked to processes associated with age-related diseases, including cancer, cardiovascular disease, diabetes, osteoporosis, and neurodegenerative diseases, all of which directly influence health in aging, and represent key targets in anti-aging therapy.
Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances.
London, United Kingdom. In Endocr Rev, 2014
With respect to the genetic etiology of isolated GHD (IGHD), mutations in known genes such as those encoding GH (GH1), GHRH receptor (GHRHR), or transcription factors involved in pituitary development, are identified in a relatively small percentage of patients suggesting the involvement of other, yet unidentified, factors.
In Nat Rev Drug Discov, 2011
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Development of growth hormone secretagogues.
Houston, United States. In Endocr Rev, 2005
I reasoned that GH pulse amplitude could be increased by four possible mechanisms: 1) increasing GHRH release; 2) amplifying GHRH signaling in somatotrophs of the anterior pituitary gland; 3) reducing somatostatin release; and 4) antagonizing somatostatin receptor signaling.